• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

byOctavio ViramontesandAliya Ramjaun
October 12, 2018
in Chronic Disease, Obstetrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Patient Basics: Trichomoniasis

Trichomoniasis is the most common sexually transmitted infection among women worldwide. Untreated, this can lead to poor reproductive outcomes and increased rates of HIV transmission. Current guidelines recommend a single 2 g dose of oral metronidazole or tinidazole as first-line treatment, and a 7-day course of oral metronidazole as second-line treatment. However, recent meta-analyses have indicated that a single-dose of metronidazole may be insufficient to cure this disease. In this open-label, randomized controlled trial, 623 women were assigned to receive either a single dose of 2 g metronidazole or 500 mg metronidazole twice daily for 7 days to determine the prevalence of trichomoniasis infection at 4 weeks after completion of treatment. Adherence to treatment was lower in the 7-day-dose group than in the single-dose group (96% vs. 99% respectively, p=0.006). Researchers found that the proportion of women who tested positive for trichomoniasis at 4 weeks was lower in the 7-day dose group than in the single-dose group (11% vs. 19%, RR 0.55, 95% CI 0.34 to 0.70, p<0.0001). The presence of bacterial vaginosis had no significant impact this result (p=0.17 for interaction). There was no significant difference in the proportion of adverse events between the two study groups. However, there were two reported spontaneous abortions among women receiving the 7-day-dose. Limitations of this study included its open-label design and low enrollment. Overall, this study supports the use of a 7-day-dose of metronidazole rather than a single-dose for women with trichomoniasis.

Click to read the study in The Lancet

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: flagylTrichomoniasis
Previous Post

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Next Post

Use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain not linked with adverse outcomes in high risk groups

RelatedReports

Health A to Z

Patient Basics: Trichomoniasis

November 30, 2014
Next Post
Tramadol and Celecoxib effective pain control for hysteroscopy

Use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain not linked with adverse outcomes in high risk groups

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

2 Minute Medicine Rewind October 15, 2018

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Quick Take: Effect of Immediate vs Delayed Pushing on Rates of Spontaneous Vaginal Delivery Among Nulliparous Women Receiving Neuraxial Analgesia: A Randomized Clinical Trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options